CN111643518B - Fishery immunopotentiator and application thereof - Google Patents
Fishery immunopotentiator and application thereof Download PDFInfo
- Publication number
- CN111643518B CN111643518B CN202010604489.9A CN202010604489A CN111643518B CN 111643518 B CN111643518 B CN 111643518B CN 202010604489 A CN202010604489 A CN 202010604489A CN 111643518 B CN111643518 B CN 111643518B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- astragalus
- immunopotentiator
- atractylodes
- fishery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Abstract
The invention discloses a fishery immunopotentiator and application thereof in aquaculture. The invention relates to a fishery immunopotentiator, which comprises the following components in percentage by mass: 33 to 75 percent of astragalus polysaccharide; 25 to 67 percent of white atractylodes rhizome polysaccharide; the sum of the mass percentages of the components is 100 percent. The fishery immunopotentiator is a combined preparation and can play a role in enhancing immunity. The astragalus polysaccharide and the atractylodes polysaccharide adopted by the invention can improve the nonspecific immunity of the fish body, but the astragalus polysaccharide and the atractylodes polysaccharide have different action modes and different action effects, are combined and have complementary actions, and the capability of improving the nonspecific immunity of the fish body is greatly enhanced. Moreover, the fish immunopotentiator has good effect. Indoor toxicity attacking tests show that the immune protection rate reaches 58.8%, and large pond application tests show that the immune protection rate reaches 64%. In addition, the raw materials adopted by the invention are all Chinese herbal medicine extracts, so that the invention is non-toxic and pollution-free, and has no hidden danger of damaging the breeding ecological environment and drug residue of aquatic products.
Description
Technical Field
The invention belongs to the technical field of prevention and treatment of aquatic animal diseases, and particularly relates to a fishery immunopotentiator and application thereof in aquaculture.
Background
With the improvement of intensive culture degree and the continuous increase of culture density in China, the cultured fishes have more and more serious diseases, and bacterial venereal disease, viral venereal disease and parasitic disease bring huge economic loss to fish culture. At present, the prevention and control of diseases are mainly based on chemical drug prevention and control, but the problems of drug resistance, environmental pollution, aquatic product drug residue and the like are easily caused by long-term repeated use of chemical drugs, and the problem of fish diseases cannot be fundamentally solved.
Disclosure of Invention
The plant polysaccharide is a natural macromolecular active substance widely existing in plants, and clinical application shows that various plant polysaccharides have an immunoregulation effect, and particularly have a remarkable curative effect in the aspect of immune enhancement. The astragalus polysaccharide is a natural active ingredient extracted from astragalus, has the functions of resisting virus, resisting oxidation, regulating body fluid and cell immunity and the like, has obvious immunity enhancement and virus resistance functions, has low price and no toxic or side effect, and is widely applied to clinical medical treatment, livestock raising and aquaculture. The main components of the atractylodes macrocephala polysaccharide are mannose and levan, and the atractylodes macrocephala polysaccharide is an important active component for promoting the immunity of the atractylodes macrocephala, and researches show that the atractylodes macrocephala polysaccharide has an obvious immunity enhancing effect, and becomes a hotspot for researching and developing feed additives due to the characteristics of naturalness, no toxicity, no resistance and the like.
In view of the problems or defects of the prior art, the invention aims to provide a fishery immunopotentiator and an application thereof in aquaculture. The invention starts from the fish body, improves the self immunity of the fish body by utilizing the fish immunopotentiator, enhances the resistance to pathogeny and adverse environment, and fundamentally reduces the occurrence of fish body diseases.
In order to achieve the first object of the present invention, the present invention adopts the following technical solutions:
a fishery immunopotentiator comprises the following components in percentage by mass:
33 to 75 percent of astragalus polysaccharide
25 to 67 percent of white atractylodes rhizome polysaccharide; the sum of the mass percentages of the components is 100 percent.
Further, according to the technical scheme, the fishery immunopotentiator comprises the following components in percentage by mass:
45 to 70 percent of astragalus polysaccharide
30-55% of atractylodes macrocephala polysaccharide; the sum of the mass percentages of the components is 100 percent.
Furthermore, according to the technical scheme, the fishery immunopotentiator comprises the following components in percentage by mass:
55 to 65 percent of astragalus polysaccharide
35-45% of atractylodes macrocephala polysaccharide; the sum of the mass percentages of the components is 100 percent.
Preferably, in the technical scheme, the fishery immunopotentiator comprises the following components in percentage by mass:
astragalus polysaccharide 60%
40% of white atractylodes rhizome polysaccharide; the sum of the mass percentages of the components is 100 percent.
The second purpose of the invention is to provide the application of the fishery immune enhancer as aquaculture feed in aquaculture.
An aquaculture feed comprises the fish immunopotentiator.
Compared with the prior art, the invention has the following obvious beneficial effects:
(1) the fishery immunopotentiator is a combined preparation and can play a role in enhancing immunity. The astragalus polysaccharide and the atractylodes polysaccharide adopted by the invention can improve the nonspecific immunity of the fish body, but the astragalus polysaccharide and the atractylodes polysaccharide have different action modes and different action effects, are combined and have complementary actions, and the capability of improving the nonspecific immunity of the fish body is greatly enhanced.
(2) The invention optimizes the proportion and has better effect. Through repeated tests, the optimal ratio range of the astragalus polysaccharide and the atractylodes polysaccharide is obtained, the optimal ratio is obtained through further optimization, and the optimal immune enhancement effect can be achieved.
(3) The fish immunopotentiator has good effect. Indoor toxicity attacking tests show that the immune protection rate reaches 58.8%, and large pond application tests show that the immune protection rate reaches 64%.
(4) The raw materials adopted by the invention are all Chinese herbal medicine extracts, so that the invention is non-toxic and pollution-free, and has no hidden danger of damaging the culture ecological environment and drug residue of aquatic products.
Detailed Description
The present invention will be described in further detail below with reference to examples. The present invention is implemented on the premise of the technology of the present invention, and the detailed embodiments and specific procedures are given to illustrate the inventive aspects of the present invention, but the scope of the present invention is not limited to the following embodiments.
Various modifications to the precise description of the invention will be readily apparent to those skilled in the art from the information contained herein without departing from the spirit and scope of the appended claims. It is to be understood that the scope of the invention is not limited to the procedures, properties, or components defined, as these embodiments, as well as others described, are intended to be merely illustrative of particular aspects of the invention. Indeed, various modifications of the embodiments of the invention which are obvious to those skilled in the art or related fields are intended to be covered by the scope of the appended claims.
For a better understanding of the invention, and not as a limitation on the scope thereof, all numbers expressing quantities, percentages, and other numerical values used in this application are to be understood as being modified in all instances by the term "about". Accordingly, unless expressly indicated otherwise, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1 (formulation screening)
1 materials and methods
1.1 test materials
Selecting astragalus polysaccharide, atractylodes polysaccharide, ganoderma polysaccharide and lentinan to compound in pairs, for example: astragalus polysaccharide: rhizoma atractylodis macrocephalae polysaccharide (the mass ratio is 1: 1); astragalus polysaccharide: ganoderma lucidum polysaccharide (mass ratio 1: 1); astragalus polysaccharide: lentinan (in a mass ratio of 1: 1); white atractylodes rhizome polysaccharide: lentinan (in a mass ratio of 1: 1); white atractylodes rhizome polysaccharide: ganoderma lucidum polysaccharide (mass ratio 1: 1); ganoderma lucidum polysaccharide: lentinan (mass ratio 1: 1). Common finless eel feed is used as a control group.
1.2 test methods
The test was divided into 7 groups, 1 control group, 6 test groups, each group being 2 replicates. Feeding common finless eel feed to a control group, and feeding to a test group by adding the following components in a mass ratio of 1:1, astragalus polysaccharide and atractylodes polysaccharide in a mass ratio of 1:1, astragalus polysaccharide and ganoderma polysaccharide, wherein the mass ratio of astragalus polysaccharide to ganoderma polysaccharide is 1:1, astragalus polysaccharide and lentinan in a mass ratio of 1:1, namely 1:1, namely 1:1 the feed of the ganoderma lucidum polysaccharide and the lentinan. The addition amount of each group of medicines (compound preparation) in the feed is 1%. Feeding twice a day, respectively feeding once at 9:00 and 16:00, wherein the feeding amount is the same for each time, and the experiment lasts for 15 days.
1.3 index determination
At the end of the test, 6 finless eels are taken from each group, blood is taken after the tail is broken, centrifugation is carried out for 10min at 4000r/min at 4 ℃ after blood coagulation, and serum is collected and frozen for standby; collecting intestinal tract, removing content, and freezing for use.
Serum determination indexes: alkaline phosphatase (ALP), acid phosphatase (ACP).
2 results of the test
The results of the survey using alkaline phosphatase and acid phosphatase in the finless eel serum are shown in Table 1.
As can be seen from Table 1, the alkaline phosphatase index alone has the following high to low order: astragalus polysaccharide: ganoderan (1: 1) > astragalus polysaccharides: atractylodes macrocephalaon polysaccharide (1: 1) > atractylodes macrocephala polysaccharide: ganoderan (1: 1) > ganoderan: lentinan (1: 1) > Astragalus polysaccharides: lentinan (1: 1) > white atractylodes rhizome polysaccharide: lentinan (1: 1) > control group, wherein astragalus polysaccharide: atractylodes macrocephalaon polysaccharide (1: 1) and astragalus polysaccharide: no significant difference (P > 0.05) exists in ganoderma lucidum polysaccharide (1: 1), and the ratio of astragalus polysaccharide: the atractylodes polysaccharide and the atractylodes polysaccharide: the ganoderan has no significant difference (P is more than 0.05), and has significant difference (P is less than 0.05) among other groups.
From the index of acid phosphatase alone, the sequence of the high to low groups is as follows: astragalus polysaccharide: ganoderan (1: 1) > astragalus polysaccharides: atractylodes macrocephalaon polysaccharide (1: 1) > astragalus polysaccharide: lentinan (1: 1) > white atractylodes rhizome polysaccharide: ganoderan (1: 1) > ganoderan: lentinan (1: 1) > white atractylodes rhizome polysaccharide: lentinan (1: 1) > control group, wherein astragalus polysaccharide: atractylodes macrocephalaon polysaccharide (1: 1) and astragalus polysaccharide: the ganoderma lucidum polysaccharide (1: 1) has no significant difference (P is more than 0.05), and has significant difference (P is less than 0.05) among other groups. The influence of each compound medicine on two enzymology indexes is inconsistent, wherein, the astragalus polysaccharide: ganoderma lucidum polysaccharide (1: 1) and astragalus polysaccharide: the two enzyme activities of the atractylodes macrocephala polysaccharide group (1: 1) have no significant difference (P is more than 0.05), and considering that the ganoderma lucidum polysaccharide is relatively expensive, astragalus polysaccharide with the second action effect is selected: atractylodis rhizoma polysaccharide is used as the preferred formula.
TABLE 1 Effect of different formulations on ALP and ACP
Note: different letters after the same column of data in the table indicate significant differences between groups (P < 0.05).
Example 2 (ratio screening)
The preferred formulation screened in example 1 was selected: the astragalus polysaccharide and the atractylodes polysaccharide are respectively prepared into a compound preparation according to the proportion in the table 2, common finless eel feed is used as a control group, finless eel serum alkaline phosphatase and acid phosphatase are used as investigation indexes, and the results show that the activity of the alkaline phosphatase and the acid phosphatase of the compound preparation prepared according to the proportion is obviously higher than that of the control group (p is less than 0.05), and when the mass ratio of the astragalus polysaccharide to the atractylodes polysaccharide is 3:1, 2:1, 1:1, 1:2, the activity of the alkaline phosphatase and the acid phosphatase is obviously higher than that of a single preparation with equal mass (p is less than 0.05), wherein the weight gain rate and the survival rate of the groups 3:1 and 2:1 are obviously higher than those of other groups (p is less than 0.05). Therefore, the optimal proportion of the compound preparation is determined to be 3: 1-1: 1.
TABLE 2 Table of different ratios of compound preparations
Example 3
The immune enhancer for fishing of the embodiment comprises the following components in percentage by mass:
astragalus polysaccharide 60%
40% of white atractylodes rhizome polysaccharide; the sum of the mass percentages of the components is 100 percent.
Example 4 Effect test of Fishery immunopotentiator on nonspecific immune index of Monopteri albi
1 materials and methods
1.1 test materials
Astragalus polysaccharides, atractylodes polysaccharides, astragalus polysaccharides: rhizoma Atractylodis Macrocephalae polysaccharide (60%: 40%)
1.2 test methods
The test was divided into 4 groups, 1 control group, 3 test groups, each group being 2 replicates. The control group is fed with common ricefield eel feed, and the test group is fed with the feed respectively added with astragalus polysaccharide, atractylodes macrocephala polysaccharide and astragalus polysaccharide: the feed contains 60 percent of atractylodes macrocephala polysaccharide (40 percent), namely astragalus membranaceus (astragalus membranaceus) for short, and the addition amount of the feed is 1 percent. Feeding twice a day, respectively feeding once at 9:00 and 16:00, wherein the feeding amount is the same for each time, and the experiment lasts for 15 days.
1.3 index determination
At the end of the test, 6 finless eels are taken from each group, blood is taken after the tail is broken, centrifugation is carried out for 10min at 4000r/min at 4 ℃ after blood coagulation, and serum is collected and frozen for standby; collecting intestinal tract, removing content, and freezing for use.
Serum determination indexes: alkaline phosphatase (ALP), acid phosphatase (ACP), Nitric Oxide Synthase (NOS), superoxide dismutase (SOD), complement C3, and complement C4.
Intestinal tract determination indexes are as follows: superoxide dismutase (SOD), Nitric Oxide Synthase (NOS), acid phosphatase (ACP), and alkaline phosphatase (AKP).
2 results of the test
2.1 serum enzymology index
As can be seen from Table 3, the ALT and AST activities in the blood serum of the finless eel in the drug feeding group are both significantly smaller than those in the control group (P < 0.05), and the difference between the drug groups is significant (P < 0.05), wherein the astragalus: the activities of the white atractylodes rhizome, astragalus polysaccharide and the white atractylodes rhizome polysaccharide are all obviously greater than those of a control group (P is less than 0.05), and the difference between the medicine groups is obvious (P is less than 0.05), wherein the white atractylodes rhizome, the astragalus: white atractylodes rhizome > astragalus polysaccharide > white atractylodes rhizome polysaccharide. The results show that 3 medicines can obviously (P is less than 0.05) reduce ALT and AST activity in serum and improve ALP, SOD, NOS and ACP activity in serum, wherein the astragalus: the effect of the white atractylodes rhizome is best.
TABLE 3 comparison of the serum enzymology index changes of different formulations
Note: different letters after the same column of data in the table indicate significant differences between groups (P < 0.05).
As can be seen from Table 4, the contents of complements C3 and C4 in the blood serum of the finless eel in the drug feeding group are both significantly higher than those in the control group (P < 0.05), and the difference between the drug groups is significant (P < 0.05), wherein: astragalus root: white atractylodes rhizome > astragalus polysaccharide > white atractylodes rhizome polysaccharide. The results show that 3 medicines can obviously (P is less than 0.05) improve the contents of complements C3 and C4 in the blood serum of the finless eel, wherein the weight ratio of astragalus: the effect of the white atractylodes rhizome is best.
TABLE 4 comparison of different formulations against complement changes in serum
| Group of | C3(μg/mL) | C4(μg/mL) |
| Astragalus polysaccharides | 2749.17±433.96b | 211.20±24.86b |
| Atractylodis rhizoma polysaccharide | 1957.56±293.67c | 164.17±12.79c |
| Astragalus polysaccharide: rhizoma Atractylodis Macrocephalae polysaccharide (60%: 40%) | 3363.35±365.01a | 254.29±16.79a |
| Control group | 1108.49±208.97d | 105.63±17.10d |
Note: different letters after the same column of data in the table indicate significant differences between groups (P < 0.05).
2.2 intestinal enzymology index
As can be seen from Table 5, the activities of SOD, NOS, ACP and AKP in intestinal tracts of finless eels fed with the medicines are all obviously higher than those of a control group, and the difference between the medicines is obvious (P is less than 0.05), wherein the ratio of astragalus: white atractylodes rhizome > astragalus polysaccharide > white atractylodes rhizome polysaccharide. 3 medicines can obviously improve the activities of SOD, NOS, ACP and AKP enzymes in intestinal tracts of the finless eels (P is less than 0.05), wherein the ratio of astragalus: the effect of the white atractylodes rhizome is best.
TABLE 5 comparison of different formulations for changes in intestinal enzymology index
Note: different letters after the same column of data in the table indicate significant differences between groups (P < 0.05).
Serum transaminase (AST, ALT and the like) is a sensitive index of damage of liver cells, and the increase of transaminase reflects the degree of damage of liver cells to a certain extent. Alkaline phosphatase (ALP), acid phosphatase (ACP) and lysozyme are main humoral immune factors in fish nonspecific immunity, and in general, the activities of the three enzymes are increased, which means that the fish body has a good immune state and the body immunity is also improved. Nitric Oxide (NOS) is produced by arginine catalyzed by nitric oxide synthase in the body, is a regulator and effector molecule in various organisms, is also a nerve messenger, and can regulate inflammation caused by infection, and can immunosuppress the inflammation, etc., so the activity of nitric oxide synthase can reflect the health condition and disease resistance of the organism to a certain extent. The important antioxidant enzyme in superoxide dismutase (SOD) can block and repair the damage of oxygen free radical in organism to cell. Complement is an important component of fish against microbial infection, and has the effects of dissolving and conditioning body target cells after activation, while C3 and C4 are main components of the complement system.
After the medicine is taken, the activity of transaminase is obviously reduced (P is less than 0.05), and the activities of alkaline phosphatase, acid phosphatase, superoxide dismutase, complement C3 and C4 in serum are obviously improved (P is less than 0.05); the activities of intestinal alkaline phosphatase, acid phosphatase, superoxide dismutase and nitric oxide synthetase are obviously improved (P is less than 0.05), which shows that the atractylis ovata polysaccharide, astragalus polysaccharide and the mixture of astragalus polysaccharide and atractylodes macrocephala polysaccharide can obviously (P is less than 0.05) improve the non-specific immunity of the finless eel, wherein the mixture has the best effect.
Example 5 Effect on disease resistance of Monopteri albi
1 materials and methods
1.1 test materials
Astragalus polysaccharides, atractylodes polysaccharides, astragalus polysaccharides: rhizoma Atractylodis Macrocephalae polysaccharide (60%: 40%)
1.2 laboratory challenge test
The test was divided into 4 groups, 1 control group, 3 test groups, each group being 2 replicates. The control group is fed with common ricefield eel feed, and the test group is fed with the feed respectively added with astragalus polysaccharide, atractylodes macrocephala polysaccharide and astragalus polysaccharide: the feed contains 60 percent of atractylodes macrocephala polysaccharide (40 percent), namely astragalus membranaceus (astragalus membranaceus) for short, and the addition amount of the feed is 1 percent. Feeding twice a day, respectively feeding once at 9:00 and 16:00, wherein the feeding amount is the same for each time, and the experiment lasts for 15 days.
After the test was completed, Aeromonas hydrophila (2.0X 10) was used8cell/mL) were challenged to each group of test fish. 20 tails of test fish were taken from each group and 0.1mL of Aeromonas hydrophila suspension was injected through the base of pectoral fin. After 96h of feeding observation, the mortality rate of each group was counted, and the Mortality Rate (MR) and the immunoprotection rate (PR) were calculated as follows.
Mortality (%) [ (initial test fish body tail-end test fish body tail)/initial test fish body tail ] × 100;
immunoprotection (%) (mortality of 1 test group/control group) × 100
1.3 Large Pond application test
Selecting 4 identical net cages (1.5m 0.7m) by a certain eel farmer of the peach, putting 100 finless eels in each net cage, feeding common finless eel feed in a control group, and feeding in test groups which are respectively added with astragalus polysaccharide, atractylodes polysaccharide and astragalus polysaccharide: the feed contains 60 percent of atractylodes macrocephala polysaccharide (40 percent), namely astragalus membranaceus (astragalus membranaceus) for short, and the addition amount of the feed is 1 percent. Feeding twice a day, and feeding once at 9:00 and 16:00 respectively. The test started on day 3 at 9 months and continued for 1 month, and the morbidity and mortality of the finless eels in each group were recorded.
1.4 test results
1.4.1 indoor toxicity test
As can be seen from table 6, after the toxicity of aeromonas hydrophila is removed, the mortality rate of the control group is 85%, the mortality rate of the astragalus polysaccharide group is 45%, the mortality rate of the atractylodes polysaccharide group is 55%, and the mortality rate of the astragalus: the group of the bighead atractylodes rhizome is 35%, the immune protection rate (P is less than 0.05%) of the mixture of the astragalus polysaccharide and the bighead atractylodes rhizome polysaccharide is remarkably higher (P is less than 0.05%) than that of the mixture of the astragalus polysaccharide (47.1%) and the bighead atractylodes rhizome polysaccharide (35.3%), and the immune effect is enhanced when the astragalus polysaccharide and the bighead atractylodes rhizome polysaccharide are mixed.
TABLE 6 comparison of immunoprotection against finless eel in different formulations
| Group of | Number/tail of offensive fish | Number of deaths/tail | The mortality rate is% | The immune protection rate% |
| Astragalus polysaccharides | 20 | 9 | 45c | 47.1b |
| Atractylodis rhizoma polysaccharide | 20 | 11 | 55b | 35.3c |
| Astragalus root: white atractylodes rhizome | 20 | 7 | 35d | 58.8a |
| Control group | 20 | 17 | 85a | - |
Note: different letters after the same column of data in the table indicate significant differences between groups (P < 0.05).
1.4.2 Large Pond application test
As can be seen from table 7, during the test period, the finless eels in the breeding area outbreaked bleeding, the mortality rate of the finless eels in the control group reached 25%, and the ratio of astragalus polysaccharide, atractylodes polysaccharide, astragalus: the mortality of the largehead atractylodes rhizome is respectively 12%, 15% and 9%, the immune protection rate (64%) of the mixture of the astragalus polysaccharide and the largehead atractylodes rhizome polysaccharide is obviously higher (P is less than 0.05) than that of the mixture of the astragalus polysaccharide (52%) and the largehead atractylodes rhizome polysaccharide (40%), and the immune effect is enhanced when the astragalus polysaccharide and the largehead atractylodes rhizome polysaccharide are mixed.
TABLE 7 comparison of the effect of different formulations on the use of big ponds
| Group of | Number/tail of test fish | Number of deaths/tail | The mortality rate is% | The immune protection rate% |
| Astragalus polysaccharides | 100 | 12 | 12c | 52b |
| Atractylodis rhizoma polysaccharide | 100 | 15 | 15b | 40c |
| Astragalus root: white atractylodes rhizome | 100 | 9 | 9d | 64a |
| Control group | 100 | 25 | 25a | - |
Note: different letters after the same column of data in the table indicate significant differences between groups (P < 0.05).
From the above results, astragalus polysaccharides, atractylodes polysaccharides, astragalus membranaceus: the three medicines of the bighead atractylodes rhizome have better immune protection effect, wherein the effect of the mixture of the astragalus polysaccharide and the bighead atractylodes rhizome polysaccharide is optimal.
Claims (3)
1. A fishery immunopotentiator characterized by: the composition consists of the following components in percentage by mass:
astragalus polysaccharide 60%
40% of white atractylodes rhizome polysaccharide; the sum of the mass percentages of the components is 100 percent.
2. Use of the fishery immunopotentiator according to claim 1 for the preparation of aquaculture feed.
3. An aquaculture feed, characterized in that: comprising the fish immunopotentiator according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010604489.9A CN111643518B (en) | 2020-06-29 | 2020-06-29 | Fishery immunopotentiator and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010604489.9A CN111643518B (en) | 2020-06-29 | 2020-06-29 | Fishery immunopotentiator and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111643518A CN111643518A (en) | 2020-09-11 |
| CN111643518B true CN111643518B (en) | 2021-06-08 |
Family
ID=72341966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010604489.9A Active CN111643518B (en) | 2020-06-29 | 2020-06-29 | Fishery immunopotentiator and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111643518B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101999645A (en) * | 2009-08-28 | 2011-04-06 | 杨军 | Polysaccharide cancer prevention tablet |
| CN106265874A (en) * | 2016-08-30 | 2017-01-04 | 四川维尔康动物药业有限公司 | A kind of Chinese medicine granules and preparation method thereof |
-
2020
- 2020-06-29 CN CN202010604489.9A patent/CN111643518B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101999645A (en) * | 2009-08-28 | 2011-04-06 | 杨军 | Polysaccharide cancer prevention tablet |
| CN106265874A (en) * | 2016-08-30 | 2017-01-04 | 四川维尔康动物药业有限公司 | A kind of Chinese medicine granules and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 植物多糖对断奶仔猪淋巴细胞增殖和细胞因子分泌的影响;邹云等;《动物营养学报》;20141231;第26卷(第1期);第210-218页，尤其是第211页右栏第1段、表1、第212页右栏第3段、第216页左栏第1段 * |
| 白术多糖免疫调节作用机制的研究进展;杨锦涛等;《中国兽药杂志》;20180630;第52卷(第6期);第80-85页，尤其是第83页左栏第3段、右栏第3段 * |
| 邹云等.植物多糖对断奶仔猪淋巴细胞增殖和细胞因子分泌的影响.《动物营养学报》.2014,第26卷(第1期), * |
| 黄芪多糖对增强水产动物免疫系统的研究;池晓娟等;《水产养殖网》;20140701;第1-4页，尤其是第1页第1段、第3页第3-4段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111643518A (en) | 2020-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102041238B (en) | Lactobacillus plantarum, method for fermenting and preparing bacteriocin of Lactobacillus plantarum, and application of Lactobacillus plantarum and bacteriocin | |
| CN104322931B (en) | A kind of special feed additive for breeding laying duck | |
| CN108841763A (en) | A kind of preparation method of zinc dense plants lactobacillus additive | |
| CN112807348B (en) | Disease-resistant and growth-promoting traditional Chinese medicine compound, and preparation and application thereof | |
| CN111643518B (en) | Fishery immunopotentiator and application thereof | |
| CN108850610B (en) | Composite plant extract feed additive and preparation method and application thereof | |
| CN114190489B (en) | Preparation method of microbial fermentation chicken feed based on hybrid broussonetia papyrifera and mugwort mixture | |
| CN105617367B (en) | Promote livestock and poultry respiratory health ferment and preparation method thereof | |
| CN112425684B (en) | Fermented feed additive with immunity enhancing effect and preparation method thereof | |
| CN115553241A (en) | Method for raising seedlings of carassius auratus pengze with high stress resistance and disease resistance | |
| CN114468176A (en) | Chinese herbal medicine additive for terminal period of egg laying and application thereof | |
| CN111642626A (en) | Feed additive for promoting growth of aquatic animals and application thereof | |
| CN110651891B (en) | Probiotic preparation for improving growth performance, immunity and nutritional quality of turbot | |
| CN103431210B (en) | Prawn feed additive and application thereof | |
| CN108041345B (en) | Disease-resistant growth-promoting maggot protein feed additive for adult American eels and preparation method and application thereof | |
| CN111096391A (en) | Anti-stress Chinese herbal medicine probiotic preparation for tilapia mossambica as well as preparation method and application of preparation | |
| CN109497287A (en) | A kind of feed addictive can promote growth of animal | |
| CN111642655A (en) | Method for developing compound Chinese herbal medicine feed additive for procambarus clarkia | |
| CN110786420A (en) | Feed additive for piglets | |
| CN110477218A (en) | A kind of nutrition prescription preventing the Yellow River carp hemorrhage and preparation method | |
| Henning | Krimpsiekte | |
| CN115040559B (en) | Traditional Chinese medicine microecological preparation for feed and application | |
| CN116268196B (en) | Plant source composite additive and application thereof | |
| AU2021106991A4 (en) | Preparation Method of Porphyra Extract and Application in Aquaculture | |
| CN103211101B (en) | Application of semen cassiae protein serving as additive of grass carp culturing feed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |